|
KMID : 1200020160400030230
|
|
Diabetes & Metabolism Journal
2016 Volume.40 No. 3 p.230 ~ p.239
|
|
|
Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
|
|
Kim Jong-Ho
Kim Sang-Soo
Baek Hong-Sun
Lee In-Kyu
Chung Dong-Jin
Sohn Ho-Sang
Bae Hak-Yeon
Kim Mi-Kyung
Park Jeong-Hyun
Choi Young-Sik
Kim Young-Il
Hahm Jong-Ryeal
Lee Chang-Won
Jo Sung-Rae
Park Mi-Kyung
Lee Kwang-Jae
Kim In-Joo
|
|
|
Abstract
|
|
|
Background: We compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes.
Methods: The present study was a multicenter, randomized, active-controlled investigation comparing the effects of vildagliptin and pioglitazone in Korean patients receiving a stable dose of metformin but exhibiting inadequate glycemic control. Each patient underwent a 16-week treatment period with either vildagliptin or pioglitazone as an add-on treatment to metformin.
Results: The mean changes in HbA1c levels from baseline were ?0.94% in the vildagliptin group and ?0.6% in the pioglitazone group and the difference between the treatments was below the non-inferiority margin of 0.3%. The mean changes in postprandial plasma glucose (PPG) levels were ?60.2 mg/dL in the vildagliptin group and ?38.2 mg/dL in the pioglitazone group and these values significantly differed (P=0.040). There were significant decreases in the levels of total, low density lipoprotein, high density lipoprotein (HDL), and non-HDL cholesterol in the vildagliptin group but increases in the pioglitazone group. The mean change in body weight was ?0.07 kg in the vildagliptin group and 0.69 kg in the pioglitazone group, which were also significantly different (P=0.002).
Conclusion: As an add-on to metformin, the efficacy of vildagliptin for the improvement of glycemic control is not inferior to that of pioglitazone in Korean patients with type 2 diabetes. In addition, add-on treatment with vildagliptin had beneficial effects on PPG levels, lipid profiles, and body weight compared to pioglitazone.
|
|
|
KEYWORD
|
|
|
Dipeptidyl peptidase 4 inhibitor, Metformin, Thiazolidinediones
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|